arrow
A

Alessandra Ferro

irccs istituto oncologico veneto (iov)
H指数:15
被引数:650

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Dissecting the prognostic role of metabolic markers in lung neuroendocrine Tumors: The MONET study

解析代谢标志物在肺神经内分泌肿瘤中的预后作用:MONET研究

2026-05-230
OAAI
Surgical outcomes after neoadjuvant chemoimmunotherapy for resectable NSCLC: a systematic review and meta-analysis

新辅助化疗免疫疗法治疗可切除非小细胞肺癌的手术结果:一项系统评价和荟萃分析

2026-04-160
PRE
Radiomic approach to support multidisciplinary tumor board decision-making in locally advanced non-small cell lung cancer

基于放射组学方法支持局部晚期非小细胞肺癌的多学科肿瘤委员会决策制定

2025-12-190
OAAI
Pathologic assessment of resected stage III non-small cell lung cancer after neoadjuvant chemotherapy: identification of additional prognostic factors

III期非小细胞肺癌新辅助化疗后切除标本的病理评估:识别额外的预后因素

2025-11-090
OAAI
Attrition with adjuvant, neoadjuvant, and perioperative immunotherapy-based treatment protocols in patients with resectable non-small-cell lung cancer. A meta-analysis of prospective trials

在可切除非小细胞肺癌患者中使用佐剂、新辅助和围手术期免疫治疗为基础的治疗方案的损耗情况。前瞻性试验的荟萃分析

2025-09-220
PREAI
Liver kinase B1 expression is associated with improved prognosis and tumor immune microenvironment features in small cell lung cancer
2025-04-040
OAAI
Clinical applications of radiomics and deep learning in breast and lung cancer: A narrative literature review on current evidence and future perspectives

放射组学和深度学习在乳腺癌和肺癌中的临床应用: 关于当前证据和未来前景的叙述性文献综述

2024-11-012
OAAI
The study of primary and acquired resistance to first-line osimertinib to improve the outcome of EGFR-mutated advanced Non-small cell lung cancer patients: the challenge is open for new therapeutic strategies

对一线奥希替尼的原发性和获得性耐药以改善EGFR突变的晚期非小细胞肺癌患者预后的研究: 新治疗策略面临的挑战

2024-04-0114
OAAI